Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Income: 2014-2024

Historic Net Income for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$110.0 million.

  • Viking Therapeutics' Net Income fell 262.79% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 139.32%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.17% down from last year.
  • Viking Therapeutics' Net Income amounted to -$110.0 million in FY2024, which was down 28.17% from -$85.8 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' Net Income registered a high of -$39.4 million during FY2020, and its lowest value of -$110.0 million during FY2024.
  • In the last 3 years, Viking Therapeutics' Net Income had a median value of -$85.8 million in 2023 and averaged -$88.2 million.
  • Data for Viking Therapeutics' Net Income shows a maximum YoY slumped of 53.80% (in 2020) over the last 5 years.
  • Over the past 5 years, Viking Therapeutics' Net Income (Yearly) stood at -$39.4 million in 2020, then slumped by 39.44% to -$55.0 million in 2021, then decreased by 25.08% to -$68.8 million in 2022, then declined by 24.78% to -$85.8 million in 2023, then declined by 28.17% to -$110.0 million in 2024.